Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from StemRIM Inc. ( (JP:4599) ) is now available.
StemRIM Inc. announced that partner Shionogi & Co. has completed patient enrollment in a global Phase 2b clinical trial of Redasemtide (S‑005151), a peptide drug derived from StemRIM’s “Regeneration-Inducing Medicine” platform, for adults with acute ischemic stroke treated within 25 hours of onset. The trial, conducted across 18 countries including Japan, the U.S. and European states, is evaluating the efficacy and safety of Redasemtide versus placebo—with or without endovascular recanalization—using the 90-day modified Rankin Scale as the primary endpoint; the company noted the program is progressing as planned and is not expected to affect full-year earnings for the fiscal year ending July 2026, underscoring steady advancement of its lead regenerative therapeutic without near-term financial disruption.
More about StemRIM Inc.
StemRIM Inc., a biotech venture originating from Osaka University, develops a novel class of “Regeneration-Inducing Medicine” designed to trigger the body’s own tissue repair and regeneration mechanisms through drug therapy rather than cell or tissue transplantation. Its lead candidates mobilize mesenchymal stem cells from bone marrow into peripheral circulation to accumulate in damaged tissues, targeting a broad range of indications including acute cerebral infarction, cardiomyopathy, osteoarthritis, chronic liver disease, pulmonary fibrosis, spinal cord and brain injuries, and various difficult-to-treat inflammatory and degenerative diseases.
Average Trading Volume: 124,157
Technical Sentiment Signal: Sell
Current Market Cap: Yen15.8B
For detailed information about 4599 stock, go to TipRanks’ Stock Analysis page.